Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Operations of Simcere’s Latest Acquisition Remain Shut Down

publication date: Apr 5, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Simcere Pharmaceutical Group (先声药业)reported that a recent acquisition, Jiangsu Yanshen Biological Technology, committed fraud with respect to its human-use rabies vaccine before Simcere bought its controlling interest in October 2009. As soon as Simcere found out about the problem, it urged Jiangsu Yanshen’s board to cease operations and review the company’s quality control. It has complied with the official investigation into the situation. More details...

Stock Symbol: (NYSE: SCR)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors